VeraLight’s Scout Eliminates Fasting From Diabetes Screening
This article was originally published in The Gray Sheet
Executive Summary
VeraLight expects to support a de novo 510(k) application for its Scout diabetes screening technology with a trial demonstrating the test's superiority to fasting plasma glucose (FPG) screening, according to CEO David Van Avermaete